ASCO Annual Meeting

Oral Presentation: A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC). Presented by, Douglas R. Adkins, M.D., Professor of Medicine, Washington University School of Medicine, St. Louis, and a principal investigator participating in the CUE-101 clinical trial


ASCO Annual Meeting

Poster Presentation: A phase 1 dose escalation and expansion study of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein, in HLA-A*0201- positive patients with WT1-positive recurrent/metastatic cancers


SITC Annual Meeting

Poster Presentation: A phase 1 trial of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers


SITC Annual Meeting

Poster Presentation: A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3L and in combination with pembrolizumab in 1L recurrent/metastatic HPV16+ head and neck cancer patients


ASCO Annual Meeting

Poster Presentation: A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer.


SITC Annual Meeting

Poster Presentation: A phase 1 study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer


SITC Annual Meeting

Poster Presentation: A phase 1, open-label, dose escalation and expansion study of CUE-102 monotherapy in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers


SITC Annual Meeting

Poster Presentation: CUE-102 selectively activates and expands WT1-specific T cells for the treatment of patients with WT1+ malignancies


American Society of Clinical Oncology (ASCO)

Poster Presentation: A Phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer


Frontiers in Cancer Immunotherapy Conference 2022 NYAS

Poster Presentation: CUE-102 Selectively Activates and Expands WT1-Specific T Cells for the Treatment of Patients with WT1+ Malignancies


BPS Annual Meeting

Poster Presentation: Integration of IL-2 signaling at the immunological synapse

Collaboration with the laboratory of Michael Dustin at the University of Oxford


SITC Annual Meeting

Poster Presentation: A phase 1 trial of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer


SITC Annual Meeting

Poster Presentation: CUE-102 selectively activates and expands WT1-specific T cells for the treatment of patients with WT1+ malignancies


T-Cell receptor-specific immunotherapeutics drive selective in vivo HIV and CMV-specific T-cell expansion in humanized mice

The Journal of Clinical Investigation; October 21, 2021 DOI: 10.1172/JCI141051

Mengyan Li, Scott J. Garforth, Kaitlyn E. O’Connor, Hang Su, Danica Lee, Alev Celikgil, Rodolfo J. Chaparro, Ronald Seidel, R. Brad Jones, Ravit Arav-Boger, Steven C. Almo and Harris Goldstein


Peptide‑HLA‑based immunotherapeutics platforms for direct modulation of antigen‑specific T cells

Nature Portfolio, Scientific Reports; September 28, 2021 DOI: 10.1038/s41598-021-98716-z

Ronald D. Seidel, Zohra Merazga, Dharma Raj Thapa, Jonathan Soriano, Emily Spaulding, Ahmet S. Vakkasoglu, Paige Ruthardt, Wynona Bautista, Steven N. Quayle, Peter A. Kiener, Simon Low, John F. Ross, Saso Cemerski, Anish Suri, Steven C. Almo & Rodolfo J. Chaparro


FOCIS Annual Meeting

Video: CUE-401: A novel IL-2/TGF-beta fusion protein for the induction of CD4+ FOXP3+ regulatory T cells

Download Poster


Frontiers in Cancer Immunotherapy Conference

Poster Presentation: Immuno-STAT™ (Selective Targeting and Alteration of T cells) Platform: Targeting Tumor Heterogeneity and Tumor Escape Mechanisms


ASIT Summit

Presentation: Directly Targeting Autoantigen-Specific T cells with Immuno-STATs


In vivo detection of antigen-specific CD8+ T cells by immuno-positron emission tomography

Nature Methods 2020; September 14, 2020 DOI: 10.1038/s41592-020-0934-5

Andrew W. Woodham, Stad H. Zeigler, Ella L. Zeyang, Stephen C. Kolifrath, Ross W. Cheloha, Mohammad Rashidian, Rodolfo J. Chaparro, Ronald D. Seidel, Scott J. Garforth, Jason L. Dearling, Maia Mesyngier, Phaneendra K. Duddempudi, Alan B. Packard, Steven C. Almo & Hidde L. Ploegh


PEGS Boston

Video Poster Presentation: Neo-STAT™: A new biologics platform for selective targeting of tumor-specific T cells with enhanced antigen modularity


Mechanistic dissection of the PD-L1:B7-1 co-inhibitory immune complex

PLOS One 2020; June 4, 2020 DOI: 10.1371/Journal PONE.0233578

Sarah C. Garrett-Thomson, Aldo Massimi, Elena V. Fedorov, Jeffrey B. Bonanno, Lisa Scandiuzzi, Brandan Hillerich, Ronald D. Seidel, III, James D. Love, Scott J. Garforth, Chandan Guha, Steven C. Almo


CUE-101, a Novel HPV16 E7 pHLA-IL-2-Fc Fusion Protein, Enhances Tumor Antigen Specific T Cell Activation for the Treatment of HPV16-Driven Malignancies

Clinical Cancer Research 2020; January 21, 2020 DOI: 10.1158/1078-0432.CCR-19-3354

Steven N Quayle, Natasha Girgis, Dharma R Thapa, Zohra Merazga, MelissaM Kemp, Alex Histed, Fan Zhao, Miguel Moreta, Paige Ruthardt, Sandrine Hulot, Alyssa Nelson, Lauren D Kraemer, Dominic R Beal, Luke Witt, Jessica Ryabin, Jonathan Soriano, Mark Haydock, Emily Spaulding, John F Ross, PeterA Kiener, Steven Almo, Rodolfo Chaparro, Ronald Seidel, Anish Suri, Saso Cemerski, Kenneth J. Pienta and Mary Ellen Simcox


SITC Annual Meeting

Poster Presentation: CUE-101, a Novel HPV16 E7:pMHC:IL-2:Fc Fusion Protein, Enhances Tumor Antigen Specific T Cell Activation for the Treatment of HPV16-Driven Malignancies


Eyeforpharma Philadelphia

Video: Diagnostic & disease detection to transform biopharma


Keystone Symposia

Poster Presentation: CUE-101, a novel Fc fusion protein for selective targeting and expansion of anti-tumor T cells for treatment of HPV-driven malignancies


SITC 2022

Cell & Gene

cell-gene-podcast-thumbnail

Empowered Patient Podcasts

empoweredpatient